7194 related articles for article (PubMed ID: 21051014)
1. Targeted molecular therapy in melanoma.
Puzanov I; Flaherty KT
Semin Cutan Med Surg; 2010 Sep; 29(3):196-201. PubMed ID: 21051014
[TBL] [Abstract][Full Text] [Related]
2. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
Shepherd C; Puzanov I; Sosman JA
Curr Oncol Rep; 2010 May; 12(3):146-52. PubMed ID: 20425073
[TBL] [Abstract][Full Text] [Related]
3. Advances in targeted therapy for melanoma.
Friedlander P; Hodi FS
Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
[TBL] [Abstract][Full Text] [Related]
4. Novel inhibitors in the treatment of metastatic melanoma.
Kalinsky K; Haluska FG
Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
[TBL] [Abstract][Full Text] [Related]
5. [New therapies targeting the genetic mutations responsible for different types of melanoma].
Botella-Estrada R; Sanmartín Jiménez O
Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
[TBL] [Abstract][Full Text] [Related]
6. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
7. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
8. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
9. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
Haluska F; Pemberton T; Ibrahim N; Kalinsky K
Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
[TBL] [Abstract][Full Text] [Related]
10. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
11. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
12. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and targeted therapy combinations in advanced melanoma.
Flaherty KT
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
[TBL] [Abstract][Full Text] [Related]
14. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
16. Prospects for non-immunological molecular therapeutics in melanoma.
Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
[TBL] [Abstract][Full Text] [Related]
17. Developments in targeted therapy in melanoma.
Amann VC; Ramelyte E; Thurneysen S; Pitocco R; Bentele-Jaberg N; Goldinger SM; Dummer R; Mangana J
Eur J Surg Oncol; 2017 Mar; 43(3):581-593. PubMed ID: 27923592
[TBL] [Abstract][Full Text] [Related]
18. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Panka DJ; Atkins MB; Mier JW
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
[TBL] [Abstract][Full Text] [Related]
19. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
Sullivan RJ; Atkins MB
Expert Opin Investig Drugs; 2010 Oct; 19(10):1205-16. PubMed ID: 20687784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
